Compare FAC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAC | CTNM |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.9M | 550.7M |
| IPO Year | 2025 | 2024 |
| Metric | FAC | CTNM |
|---|---|---|
| Price | $5.41 | $15.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 460.0K | 243.7K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.24 | $5.71 |
| 52 Week High | $15.40 | $16.91 |
| Indicator | FAC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 27.98 | 50.66 |
| Support Level | $4.27 | $13.62 |
| Resistance Level | $5.76 | $15.52 |
| Average True Range (ATR) | 0.65 | 1.03 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 49.55 | 38.30 |
Factorial Energy Inc is an American solid-state battery innovator backed by In-Q-Tel - the not-for-profit strategic investor for the U.S. national security community and America's allies - and Mercedes-Benz, Stellantis, Hyundai, and Kia. Through its proprietary FEST and Solstice platforms, engineered for scalable manufacturing, it delivers industry performance across defense, space, and energy storage applications. Mercedes-Benz's real-world road testing in a lightly modified test vehicle achieved over 1,200 km of range on a single charge, while Stellantis-lab testing verified 77 Ah cells demonstrating high energy density, fast-charging, and robust use for energy and power performance across temperature extremes.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.